Literature DB >> 16933810

Medicine use by Finnish female conscripts during voluntary military service.

Kari Linden1, Vesa Jormanainen, Kirsi Pietilä, Timo Sahi.   

Abstract

OBJECTIVE: The goal was to assess the prevalence of prescribed and nonprescribed medicine use, use predictors, and origin of medicines for Finnish female conscripts during their voluntary military service.
METHODS: An anonymous mail survey was conducted in April 1999 among all Finnish female conscripts on duty.
RESULTS: Of the respondents (N = 177; response rate, 68%), 61% had used at least one medicine in the 2 weeks preceding the study, 44% prescribed and 31% nonprescribed medicines. Most of the prescribed medicines were provided by Finnish Defence Forces health care, whereas most of the nonprescribed medicines were of civilian origin. The consumption of prescribed and nonprescribed medicines was differently related to respondents' background variables. Common overall medicine use and use of over-the-counter analgesics and stimulants and their association with potentially negative health behaviors may contribute to inappropriate medicine use.
CONCLUSION: Finnish female conscripts commonly use prescribed and nonprescribed medicines. The importance of sufficient medication information for female conscripts is emphasized.

Mesh:

Substances:

Year:  2006        PMID: 16933810     DOI: 10.7205/milmed.171.8.710

Source DB:  PubMed          Journal:  Mil Med        ISSN: 0026-4075            Impact factor:   1.437


  2 in total

1.  Sharing prescription medicines: results of a survey of community pharmacy clients in Auckland, New Zealand.

Authors:  Alexandra Gascoyne; Kebede Beyene; Joanna Stewart; Trudi Aspden; Janie Sheridan
Journal:  Int J Clin Pharm       Date:  2014-11-02

2.  Stress and use of over-the-counter analgesics: prevalence and association among Danish 25 to 44-year-olds from 1994 to 2005.

Authors:  Vibeke Koushede; Ola Ekholm; Bjørn E Holstein; Anette Andersen; Ebba Holme Hansen
Journal:  Int J Public Health       Date:  2010-09-01       Impact factor: 3.380

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.